A DS-1 like G9P[6] human strain CDC-6 as a new rotavirus vaccine candidate |
| |
| Affiliation: | 1. Research & Development, Seqirus, Cambridge, MA, United States;2. Takeda Vaccines, Cambridge, MA, United States;3. GSK Vaccines, Rockville, MD, United States;1. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States;2. LimmaTech Biologics AG, Schlieren, Switzerland;3. Walter Reed Army Institute of Research, Silver Spring, MD, United States;4. Naval Medical Research Center, Silver Spring, MD, United States;5. Now at PATH Center for Vaccine Innovation and Access, Washington, DC, United States |
| |
| Abstract: | Human rotavirus vaccine Rotarix® (G1P[8]) has shown broad cross protection against homotypic and heterotypic Wa-like human rotavirus strains among children worldwide. This vaccine, however, appears to induce slightly less or non-consistent protection against DS-1 like rotavirus P[4] strains in some settings. In addition, children who are secretor or Lewis-negative and are vaccinated with Rotarix® often experience breakthrough infection with P[6] strains. By contrast, P[6] strains infect all children, irrespective of their secretor or Lewis status. In the present study, we report successful adaptation of a DS-1 like human rotavirus G9P[6] strain (CDC-6) to high growth in Vero cells and identify sequence changes that may be critical for enhanced growth in vitro and attenuation in vivo. This human G9P[6] strain could serve as a promising new and potential low-cost vaccine candidate for global use, particularly in targeted population with secretor or Lewis-negative status and high prevalent DS-1 like P[6] strains. |
| |
| Keywords: | Rotavirus Rotavirus vaccine CDC-6 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
